论文部分内容阅读
Catheter ablation of atrial fibrillation (AF) has opened a new door to cure AF and is fundamental-ly changing our clinical practice. The emergence of novel anticoagulation drugs and antiarrhythmic agents also bring us great hope and enriches our therapeutic options. When we reconsider the strategy of AF with regards to symptom relief and prognosis improvement, perhaps we will achieve new understanding and judgment. The newly issued study by Forleo[1] evaluated the safety and efficacy of ablation therapy in type 2 diabetes mellitus patients with drug refractory AF. The results showed that patients who received a single ablation procedure but without medications were more free of AF than patients in the antiarrhythmic drugs (AADs) group(20% vs 57.1% ,P =0.001). In the ablation group, a significant improvement in quality-of-life (QoL) scores as compared with AADs group was also observed. Another A4 clinical trial was a randomized multicenter clinical study that compared the relative merits between pharmacology and catheter ablation of AF[2]. At the 1-year follow-up, patients in ablation group experienced lower re-currence than patients in AADs group (11% vs 77%, P